PL1685849T3 - Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego - Google Patents

Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego

Info

Publication number
PL1685849T3
PL1685849T3 PL04799810T PL04799810T PL1685849T3 PL 1685849 T3 PL1685849 T3 PL 1685849T3 PL 04799810 T PL04799810 T PL 04799810T PL 04799810 T PL04799810 T PL 04799810T PL 1685849 T3 PL1685849 T3 PL 1685849T3
Authority
PL
Poland
Prior art keywords
pde
inhibitors
interstitial cystitis
treatment
pelvic pain
Prior art date
Application number
PL04799810T
Other languages
English (en)
Inventor
Miki Kobayashi
Satoshi Kubo
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PL1685849T3 publication Critical patent/PL1685849T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04799810T 2003-11-20 2004-11-18 Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego PL1685849T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003390137 2003-11-20
EP04799810A EP1685849B1 (en) 2003-11-20 2004-11-18 Pde 4 inhibitors for the treatment of interstitial cystitis
PCT/JP2004/017521 WO2005049087A1 (ja) 2003-11-20 2004-11-18 慢性骨盤痛症候群治療剤

Publications (1)

Publication Number Publication Date
PL1685849T3 true PL1685849T3 (pl) 2012-07-31

Family

ID=34616327

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04799810T PL1685849T3 (pl) 2003-11-20 2004-11-18 Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego

Country Status (9)

Country Link
US (1) US20070167450A1 (pl)
EP (1) EP1685849B1 (pl)
JP (1) JPWO2005049087A1 (pl)
AT (1) ATE542546T1 (pl)
CA (1) CA2544322C (pl)
ES (1) ES2378374T3 (pl)
PL (1) PL1685849T3 (pl)
PT (1) PT1685849E (pl)
WO (1) WO2005049087A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509984A (ja) * 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のpde阻害剤およびそれらの組合せ
WO2009088054A1 (ja) 2008-01-11 2009-07-16 Astellas Pharma Inc. 精巣の疼痛又は不快感行動及び頻尿併発モデル動物
US20130252924A1 (en) * 2010-11-11 2013-09-26 Akron Molecules Gmbh Compounds and Methods for Treating Pain
WO2013155123A1 (en) * 2012-04-10 2013-10-17 Georgia State University Research Foundation, Inc. Compositions and methods for treating otitis media and other conditions with inhibitors of cyld
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59410119D1 (de) * 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
GB9404706D0 (en) 1994-03-11 1994-04-27 Smithkline Beecham Corp Compounds
WO1996006843A1 (en) 1994-08-29 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Novel naphthyridine derivative and medicinal composition thereof
NZ322197A (en) 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
JPH11292878A (ja) 1998-04-09 1999-10-26 Yamanouchi Pharmaceut Co Ltd イミダゾナフチリジン誘導体
JPH11292877A (ja) 1998-04-09 1999-10-26 Yamanouchi Pharmaceut Co Ltd 1,4−ジ置換ピリドピラジン誘導体
CA2331844A1 (en) 1998-05-07 1999-11-11 University Of Maryland, Baltimore A method for diagnosing and treating chronic pelvic pain syndrome
TWI262919B (en) * 1999-10-25 2006-10-01 Yamanouchi Pharma Co Ltd Naphthyridine derivative
GB0011802D0 (en) 2000-05-16 2000-07-05 Smithkline Beecham Method for enhancing cognitive function
EP1161949A1 (en) * 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
WO2002069906A2 (en) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
DE60230266D1 (de) * 2001-06-15 2009-01-22 Astellas Pharma Inc Phenylpyridincarbonyl piperazinderivate
US7101847B2 (en) * 2002-10-11 2006-09-05 Milkhaus Laboratory, Inc. Method of treating chronic pelvic pain syndrome by administration of chorionic gonadotropin

Also Published As

Publication number Publication date
US20070167450A1 (en) 2007-07-19
EP1685849B1 (en) 2012-01-25
ES2378374T3 (es) 2012-04-11
WO2005049087A1 (ja) 2005-06-02
EP1685849A1 (en) 2006-08-02
CA2544322A1 (en) 2005-06-02
JPWO2005049087A1 (ja) 2007-06-07
PT1685849E (pt) 2012-02-15
EP1685849A4 (en) 2008-12-31
CA2544322C (en) 2012-05-08
ATE542546T1 (de) 2012-02-15

Similar Documents

Publication Publication Date Title
AU2002321105A1 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
DE122007000056I1 (de) Beta-amino-tetrahydroimidazo (1,2-A)pyrazine und-tetrahydrotriazolo(4,3-A)pyrazine als dipeptidyl peptidase Inhibitoren zur Behandlung oder preventionvon Diabetes
SI1983000T1 (sl) Postopek za zdravljenje multiple skleroze z zaviranjem aktivnosti il-17
WO2004093803A3 (en) Photochemotherapeutic compounds for use in treatment of pin1-associated states
IL144144A0 (en) Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
PT2194049E (pt) N-óxidos de derivados de n-fenil-2-pirimidina-amina
ATE465756T1 (de) Antitumoreffekt-verstärker
WO2004073623A3 (en) Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
WO2004019863A3 (en) Combination therapy for treatment of fibrotic disorders
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
GB0226434D0 (en) Combination product
ITTO20021024A1 (it) Trattamento di superficie per componenti ferrosi.
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
PL368271A1 (pl) Sposób leczenia i zapobiegania bólowi i zapaleniuglukozaminą i inhibitorem selektywnym cyklooksygenazy-2 i kompozycje je zawierające
PL1685849T3 (pl) Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
WO2003053365A3 (en) Syn3 compositions and methods
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
WO2002039958A3 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
NO20062229L (no) Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er)
ZA200308172B (en) Use of IL-18 inhibitors for treating or preventing CNS injuries.
TW200503672A (en) 2-aminobenzoyl derivatives
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases